

LILRA1/LIR-6/CD85i Protein, Human, Recombinant (His & Avi), Biotinylated

General Information

Synonyms:	LILRA1;LIR-6;LIR6MGC126563;LIR6;CD85i
Protein Construction:	Pro17-Asn461
Species:	Human
Expression Host:	HEK293 Cells
Accession:	O75019-1
Molecular Weight:	51.4 kDa (predicted). Due to glycosylation, the protein migrates to 70-80 kDa based on Tris-Bis PAGE result.

QC Testing

Biological Activity:	Activity has not been tested. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first.
Purity:	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Endotoxin:	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation:	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.

Preparation and Storage

Reconstitution:

Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

Protein Background

LILRA1, also known as CD85i and LIR-6, is an approximately 70 kDa variably glycosylated transmembrane protein that regulates immune cell activation. Mature human LILRA1 consists of a 445 amino acid (aa) extracellular domain (ECD) with 4 Ig-like domains, a 21 aa transmembrane segment, and a 7 aa cytoplasmic tail. LILRA1 may act as receptor for class I MHC antigens.

Reference

The MHC class I-LILRB1 signalling axis as a promising target in cancer therapy[J]. Scandinavian Journal of Immunology, 2019.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481